... whose disease progressed through standard of care treatment for nonclear RCC. However, genetic analysis revealed a germline pathogenic variant of fumarate hydratase (FH) gene, and the patient had a sustained and durable response to pazopanib. [email protected] 27 07 2022 9 11 2022...

... metastasis has not yet been fully elucidated. We report a case of a Filipino male with renal cell carcinoma and brain metastasis who underwent stereotactic radiosurgery of his right frontal lesion followed by pazopanib taken initially at 800 mg/day and then decreased to 600 mg/day. A significant increase...

... challenges due to the rarity of both diseases and lack of established guidelines. We propose three treatment approaches including pazopanib for salvage therapy of EH of the bone and minimally invasive surgical resection which in these cases lead to complete symptom relief and tumor stabilization upheld over...

.... This response allowed for her enrollment in a phase I trial of an oral chemotherapeutic agent; however, she eventually developed progressive disease and was taken off the study. She was then treated with the multifunctional TKI pazopanib. Pazopanib was initiated at 800 mg daily, but increased bleeding from her...

... of which she was prescribed pazopanib, to which she showed a dramatic clinical response after 1 month, followed by a durable response for 1 year. Tyrosine kinase inhibitors such as pazopanib are potentially useful in paraganglioma, with further studies needed to understand the role of vascular endothelial...

... chemotherapy. Gemcitabine/Taxotere was given as second-line therapy and pembrolizumab as third-line therapy, with continued disease progression after 2 cycles of both regimens. The patient was switched to fourth-line therapy with pazopanib and had a partial response for 9 months. This case illustrates...

...Takashi Kawahara; Tappei Takeshima; Yasuhide Miyoshi; Noboru Nakaigawa; Masahiro Yao; Mikiko Tanabe; Hiroji Uemura COMPARZ study revealed no marked differences in terms of the progression free survival and overall survival between sunitinib and pazopanib treatment. Regarding the quality of life...

... reports have described their role in cardiac metastases. We present a case of a left ventricular metastasis from RCC that was managed with pazopanib therapy. Case Report: A 74-year-old male with stage I RCC underwent right nephrectomy in 2004 and right lung metastasis resection in 2009. He was well till...

...Diogo Alpuim Costa; Susana Baptista de Almeida; Pedro Coelho Barata; António Quintela; Pedro Cabral; Ana Afonso; João Maia Silva In phase II/III trials, cutaneous side effects of pazopanib were reported in less than 20% of patients, with only 1–3% being grade 3/4. We present a case of a 66-year-old...

...Jennifer M. Logue; Bahram Kiani; Rhonda L. Bitting Background: The VEGF inhibitor pazopanib is a widely used first-line therapy for the treatment of advanced renal cell carcinoma. Potential drug-drug interactions and toxicities may be underrecognized. Case Presentation: A 73-year-old woman...

...Yoshiro Nakahara; Tomoya Fukui; Ken Katono; Yuuki Nishizawa; Yusuke Okuma; Masachika Ikegami; Jiichiro Sasaki; Noriyuki Masuda Pazopanib, a multitargeting tyrosine kinase inhibitor, has single-agent activity in patients with advanced soft-tissue sarcoma. Herein, we describe 2 cases of pneumothorax...

.... After subsequent progression through sunitinib and second-line bevacizumab, both individuals again had disease response and subsequent stabilization from pazopanib. Alveolar soft part sarcoma Soft tissue sarcoma Sunitinib Pazopanib 1 09 2016 1 09 2016 17 10 2016 © 2016...

... with primary metastatic cardiac angiosarcoma who showed a severe hypersensitivity reaction to conventional chemotherapy with taxanes but an excellent response to treatment with the multitargeted receptor tyrosine kinase inhibitor pazopanib. [email protected] 24 05 2016 24 05...

..., and the prognosis after metastasis is poor. We report a case of multiple lung metastases of an epithelioid sarcoma originating in the inguinal area that we treated with the multikinase inhibitor pazopanib. The patient was a 38-year-old male who began to experience discomfort in his left inguinal area. Magnetic...

...Kazumichi Kawakubo; Hiroo Hata; Hiroshi Kawakami; Masaki Kuwatani; Shuhei Kawahata; Kimitoshi Kubo; Keisuke Imafuku; Shinya Kitamura; Naoya Sakamoto Pazopanib is an oral angiogenesis inhibitor targeting vascular endothelial growth factor receptors, platelet-derived growth factor receptors, and c...

...Robert Foerster; Thomas Welzel; Juergen Debus; Carsten Gruellich; Dirk Jaeger; Karin Potthoff A 62-year-old female patient with metastatic renal cell carcinoma under third-line treatment with pazopanib for 8 weeks suddenly developed severe headaches, grand mal seizures and paresis of the left arm...